id stringlengths 9 11 | source stringclasses 1
value | title stringlengths 15 560 | text stringlengths 2k 153k |
|---|---|---|---|
PMC10052104 | core_pubmed_pmc | Cyclodextrin-Based Polymeric Drug Delivery Systems for Cancer Therapy | Cyclodextrin-Based Polymeric Drug Delivery Systems for Cancer Therapy Abstract Abstract Cyclodextrins (CDs) are one of the most extensively studied cyclic-oligosaccharides due to their low toxicity, good biodegradability and biocompatibility, facile chemical modification, and unique inclusion capacity. However, problem... |
PMC11837431 | core_pubmed_pmc | Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV | Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV Abstract Abstract VRC07-523LS is a safe and well-tolerated monoclonal antibody (mAb) targeting the CD4 binding site on the HIV envelope (Env) tri... |
PMC8071277 | core_pubmed_pmc | Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer’s Disease | Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer’s Disease Abstract Background: Mood disorders represent a risk factor for dementia and are present in over 60% of cases with Alzheimer’s disease (AD). More than 80% variability in drug pharmacokinetics and pharmacodynamic... |
PMC8897336 | core_pubmed_pmc | New possibilities for neuroprotection in neonatal hypoxic-ischemic encephalopathy | New possibilities for neuroprotection in neonatal hypoxic-ischemic encephalopathy Abstract Abstract Around 0.75 million babies worldwide suffer from moderate or severe hypoxic-ischemic encephalopathy (HIE) each year resulting in around 400,000 babies with neurodevelopmental impairment. In 2010, neonatal HIE was associa... |
PMC5859341 | core_pubmed_pmc | Antibodies, synthetic peptides and related constructs for planetary health based on green chemistry in the Anthropocene | Antibodies, synthetic peptides and related constructs for planetary health based on green chemistry in the Anthropocene Abstract Abstract The contemporary Anthropocene is characterized by rapidly evolving complex global challenges to planetary health vis-a-vis sustainable development, yet innovation is constrained unde... |
PMC11240368 | core_pubmed_pmc | In Vitro Antibacterial Activities of Fosfomycin against Escherichia coli Isolates from Canine Urinary Tract Infection | In Vitro Antibacterial Activities of Fosfomycin against Escherichia coli Isolates from Canine Urinary Tract Infection Abstract Abstract Simple Summary Canine urinary tract infections (UTIs) caused by Escherichia coli ( E. coli ) are common in dogs. While beta-lactams and trimethoprim-sulfonamides are typically the firs... |
PMC12083208 | core_pubmed_pmc | Isoniazid-Associated Serotonin Toxicity in the Critical Care Setting: A Case Report | Isoniazid-Associated Serotonin Toxicity in the Critical Care Setting: A Case Report Abstract Abstract Serotonin syndrome presents with the triad of neuromuscular excitability, autonomic disturbance, and altered mental status, resulting from excess serotonergic tone. Isoniazid (INH), a core agent for the management of t... |
PMC5814521 | core_pubmed_pmc | Clinical Pharmacokinetics and Pharmacodynamics of Micafungin | Clinical Pharmacokinetics and Pharmacodynamics of Micafungin Abstract Micafungin is a selective inhibitor of the synthesis of fungal 1,3-β- d -glucan, an essential component of the fungal cell wall. It is available as a powder for infusion only and is registered for the treatment of invasive and esophageal candidiasis ... |
PMC5994030 | core_pubmed_pmc | The use of clonidine in elderly patients with delirium; pharmacokinetics and hemodynamic responses | The use of clonidine in elderly patients with delirium; pharmacokinetics and hemodynamic responses Abstract Abstract Background The Oslo Study of Clonidine in Elderly Patients with Delirium (LUCID) is an RCT investigating the effect of clonidine in medical patients > 65 years with delirium. To assess the dosage regimen... |
PMC7221516 | core_pubmed_pmc | Development and In Vitro and In Vivo Evaluation of Microspheres Containing Sodium N -[8-(2-hydroxybenzoyl)amino]caprylate for the Oral Delivery of Berberine Hydrochloride | Development and In Vitro and In Vivo Evaluation of Microspheres Containing Sodium N -[8-(2-hydroxybenzoyl)amino]caprylate for the Oral Delivery of Berberine Hydrochloride Abstract Microspheres containing absorption enhancer (sodium N -[8-(2-hydroxybenzoyl)amino]caprylate, SNAC) were developed to enhance the oral bioava... |
PMC3705392 | core_pubmed_pmc | An HPLC Method for Microanalysis and Pharmacokinetics of Marine Sulfated Polysaccharide PSS-Loaded Poly Lactic- co -Glycolic Acid (PLGA) Nanoparticles in Rat Plasma | An HPLC Method for Microanalysis and Pharmacokinetics of Marine Sulfated Polysaccharide PSS-Loaded Poly Lactic- co -Glycolic Acid (PLGA) Nanoparticles in Rat Plasma Abstract Abstract This study was aimed at developing a sensitive and selective HPLC method with postcolumn fluorescence derivatization for the detection of... |
PMC11173508 | core_pubmed_pmc | Pharmacokinetics and Tissue Distribution of Itampolin A following Intragastric and Intravenous Administration in Rats Using Ultra-High-Performance Liquid Chromatography–Tandem Mass Spectrometry | Pharmacokinetics and Tissue Distribution of Itampolin A following Intragastric and Intravenous Administration in Rats Using Ultra-High-Performance Liquid Chromatography–Tandem Mass Spectrometry Abstract Abstract Itampolin A, a natural brominated tyrosine alkaloid isolated from the sponge Iotrochota purpurea , has been ... |
PMC8043779 | core_pubmed_pmc | Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications | Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications Abstract Mesenchymal stem/stromal cells (MSCs) are a promising resource for cell-based therapy because of their high immunomodulation ability, tropism towards inflamed and injured tissues, and... |
PMC11884232 | core_pubmed_pmc | Relationship of dihydroergotamine pharmacokinetics, clinical efficacy, and nausea—A narrative review | Relationship of dihydroergotamine pharmacokinetics, clinical efficacy, and nausea—A narrative review Abstract Abstract Objective To assess the relationships between dihydroergotamine (DHE) pharmacokinetic (PK) parameters, clinical efficacy, and nausea incidence to determine a DHE PK profile that optimizes efficacy whil... |
PMC8149352 | core_pubmed_pmc | The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study | The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study Abstract Abstract Purpose Pamiparib is an investigational, selective, oral poly(ADP-ribose) polymerase 1/2 (PARP1/2)... |
PMC11985459 | core_pubmed_pmc | Escitalopram oxalate-loaded chitosan nanoparticle in situ gel formulation intended for direct nose-to-brain delivery: in vitro , ex vivo , and in vivo pharmacokinetic evaluation | Escitalopram oxalate-loaded chitosan nanoparticle in situ gel formulation intended for direct nose-to-brain delivery: in vitro , ex vivo , and in vivo pharmacokinetic evaluation Abstract Abstract Introduction: Escitalopram oxalate (ESCI) is a biopharmaceutical classification system (BCS) class II antidepressant drug, t... |
PMC12232974 | core_pubmed_pmc | Effect of Rifampicin on the Pharmacokinetics of Valemetostat and Its Primary Metabolite: A Phase 1 Study in Healthy Participants | Effect of Rifampicin on the Pharmacokinetics of Valemetostat and Its Primary Metabolite: A Phase 1 Study in Healthy Participants Abstract ABSTRACT Valemetostat tosylate (valemetostat) is a dual inhibitor of enhancer of zeste homolog (EZH)2 and EZH1, approved in Japan for the treatment of relapsed or refractory peripher... |
PMC9008124 | core_pubmed_pmc | Algorithmic multiscale analysis for the FcRn mediated regulation of antibody PK in human | Algorithmic multiscale analysis for the FcRn mediated regulation of antibody PK in human Abstract A demonstration is provided on how algorithmic asymptotic analysis of multi-scale pharmacokinetics (PK) systems can provide (1) system level understanding and (2) predictions on the response of the model when parameters va... |
PMC6756841 | core_pubmed_pmc | Bioequivalence Study Of A Fixed-Dose Combination Tablet Containing Melitracen 10 mg And Flupentixol 0.5 mg In Healthy Chinese Volunteers Under Fasted And Fed Conditions | Bioequivalence Study Of A Fixed-Dose Combination Tablet Containing Melitracen 10 mg And Flupentixol 0.5 mg In Healthy Chinese Volunteers Under Fasted And Fed Conditions Abstract Purpose A fixed-dose combination (FDC) tablet of melitracen/flupentixol has been widely used for depression. The purpose of this study was to ... |
PMC9739296 | core_pubmed_pmc | Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy | Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy Abstract The tumor necrosis factor (TNF) superfamily member TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in cancer cells via death receptor (DR) activation with little toxicity to normal ce... |
PMC9319520 | core_pubmed_pmc | The Usefulness of In Vitro Percutaneous Absorption Experiments Applying the Infinite Dose Technique to Predict In Vivo Plasma Levels: Comparison of Model-Predicted and Observed Plasma Concentrations of Nortriptyline in Rats | The Usefulness of In Vitro Percutaneous Absorption Experiments Applying the Infinite Dose Technique to Predict In Vivo Plasma Levels: Comparison of Model-Predicted and Observed Plasma Concentrations of Nortriptyline in Rats Abstract Abstract The aims of this study were to evaluate the feasibility of a nortriptyline (NT... |
PMC3967144 | core_pubmed_pmc | Drug Development for Pediatric Populations: Regulatory Aspects | Drug Development for Pediatric Populations: Regulatory Aspects Abstract Pediatric aspects are nowadays integrated early in the development process of a new drug. The stronger enforcement to obtain pediatric information by the regulatory agencies in recent years resulted in an increased number of trials in children. Spe... |
PMC12142702 | core_pubmed_pmc | Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application | Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application Abstract ABSTRACT Substantial research has been conducted to identify an efficient treatment for Alzheimer's disease (AD). Existing treatments, including cholinesterase inhibitors and N‐methyl D‐aspartate (NMD... |
PMC11494823 | core_pubmed_pmc | Understanding the mechanisms of food effect on omaveloxolone pharmacokinetics through physiologically based biopharmaceutics modeling | Understanding the mechanisms of food effect on omaveloxolone pharmacokinetics through physiologically based biopharmaceutics modeling Abstract Abstract Omaveloxolone is a nuclear factor (erythroid‐derived 2)‐like 2 activator approved in the United States and the European Union for the treatment of patients with Friedre... |
PMC9500303 | core_pubmed_pmc | Phytochemicals That Interfere With Drug Metabolism and Transport, Modifying Plasma Concentration in Humans and Animals | Phytochemicals That Interfere With Drug Metabolism and Transport, Modifying Plasma Concentration in Humans and Animals Abstract Phytochemicals (Pch) present in fruits, vegetables and other foods, are known to inhibit or induce drug metabolism and transport. An exhaustive search was performed in five databases covering ... |
PMC7066277 | core_pubmed_pmc | Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor | Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor Abstract Background Dotinurad, a novel selective urate reabsorption inhibitor, exerts a serum uric acid-lowering effect by selectively inhibiting urate transporte... |
PMC7079111 | core_pubmed_pmc | Time‐to‐Event Modeling for Remimazolam for the Indication of Induction and Maintenance of General Anesthesia | Time‐to‐Event Modeling for Remimazolam for the Indication of Induction and Maintenance of General Anesthesia Abstract Abstract Remimazolam is an ultra‐short‐acting benzodiazepine being investigated for induction and maintenance of general anesthesia and for procedural sedation. This dose‐response analysis of 4 phase 2‐... |
PMC11415041 | core_pubmed_pmc | Extraction of ketamine and dexmedetomidine by extracorporeal life support circuits ★ | Extraction of ketamine and dexmedetomidine by extracorporeal life support circuits ★ Abstract Background : Patients supported with extracorporeal life support (ECLS) circuits such as ECMO and CRRT often require high doses of sedatives and analgesics, including ketamine and dexmedetomidine. Concentrations of many medica... |
PMC7545991 | core_pubmed_pmc | First clinical study of a pegylated diabody 124 I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers | First clinical study of a pegylated diabody 124 I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers Abstract Abstract Through protein engineering and a novel pegylation strategy, a diabody specific to tumor-associated glycoprotein 72 (TAG-72) (PEG-AVP0458) has been created to optimi... |
PMC11250459 | core_pubmed_pmc | Pharmacokinetics, safety, and efficacy of Fuqi Guben Gao in the treatment of kidney-yang deficiency syndrome: a randomized, double-blind phase I trial | Pharmacokinetics, safety, and efficacy of Fuqi Guben Gao in the treatment of kidney-yang deficiency syndrome: a randomized, double-blind phase I trial Abstract Introduction: Fuqi Guben Gao (FQGBG) is a botanical drug formulation composed of FuZi (FZ; Aconitum carmichaelii Debeaux [Ranunculaceae; Aconiti radix cocta]), ... |
PMC12528724 | core_pubmed_pmc | A preliminary study of the physiological and perceptual effects of GLP-1 receptor agonists during alcohol consumption in people with obesity | A preliminary study of the physiological and perceptual effects of GLP-1 receptor agonists during alcohol consumption in people with obesity Abstract Any increase in alcohol use is associated with an increase in risk of illness and mortality and consequences of chronic alcohol use include cancer, hypertension, heart an... |
PMC7359948 | core_pubmed_pmc | Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis | Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis Abstract Abstract Anti‐tumor necrosis factor (anti‐TNF) drugs are often prescribed for the treatment of rheumatoid arthritis (RA) and other immune‐mediated inflammatory diseas... |
PMC6937718 | core_pubmed_pmc | Prophylactic use of levosimendan in pediatric patients undergoing cardiac surgery: a prospective randomized controlled trial | Prophylactic use of levosimendan in pediatric patients undergoing cardiac surgery: a prospective randomized controlled trial Abstract Background The administration of levosimendan prophylactically to patients undergoing cardiac surgery remains a controversial practice, and few studies have specifically assessed the val... |
PMC8452292 | core_pubmed_pmc | Estimating fetal exposure to the P‐gp substrates, corticosteroids, by PBPK modeling to inform prevention of neonatal respiratory distress syndrome | Estimating fetal exposure to the P‐gp substrates, corticosteroids, by PBPK modeling to inform prevention of neonatal respiratory distress syndrome Abstract Abstract We have previously developed a maternal‐fetal physiologically‐based pharmacokinetic (m‐f PBPK) model to dynamically predict (and verify) fetal‐maternal exp... |
PMC7376802 | core_pubmed_pmc | Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects | Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects Abstract Introduction Ultra rapid lispro (URLi) is a novel insulin lispro formulation that was developed to more closely match physiological insulin secretion. The aims of this study were to demonstrate the bioequivalence (BE) of... |
PMC12077683 | core_pubmed_pmc | In silico analysis to explore the therapeutic potential of propolis-derived small molecules as matriptase inhibitors to suppress breast cancer growth and metastasis | In silico analysis to explore the therapeutic potential of propolis-derived small molecules as matriptase inhibitors to suppress breast cancer growth and metastasis Abstract Abstract Breast cancer is a major cause of death in women, and various drug therapies are used for its treatment. However, current therapies have ... |
PMC7951102 | core_pubmed_pmc | Isradipine plasma pharmacokinetics and exposure–response in early Parkinson’s disease | Isradipine plasma pharmacokinetics and exposure–response in early Parkinson’s disease Abstract Abstract Objectives Isradipine is a dihydropyridine calcium channel inhibitor that has demonstrated concentration‐dependent neuroprotective effects in animal models of Parkinson’s disease (PD) but failed to show efficacy in a... |
PMC7359989 | core_pubmed_pmc | Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review | Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review Abstract Abstract Irinotecan-based regimens are used worldwide for the treatment of several recurrent or advanced gastrointestinal malignancies. In this paper we describe the cases of four patients treated in our institution who develope... |
PMC11485705 | core_pubmed_pmc | Interference from anti-drug antibodies on the quantification of insulin: a comparison of an LC-MS/MS assay and immunoassays | Interference from anti-drug antibodies on the quantification of insulin: a comparison of an LC-MS/MS assay and immunoassays Abstract Abstract Aim: This study aims to compare the anti-drug antibody (ADA) interference in four pharmacokinetic (PK) assays across different platforms (AlphaLISA, Gyrolab, LC-MS/MS) and to dev... |
PMC5306058 | core_pubmed_pmc | Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study | Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study Abstract Purpose Cabazitaxel has not been studied in patients with hepatic impairment (HI). This phase I study assessed cabazitaxel safety and pharmacokinetics in patients with HI. Methods Patients with advan... |
PMC12014539 | core_pubmed_pmc | Population pharmacokinetics and dose optimization of voriconazole in patients with COVID-19-associated pulmonary aspergillosis | Population pharmacokinetics and dose optimization of voriconazole in patients with COVID-19-associated pulmonary aspergillosis Abstract Objectives The study aimed to investigate the pharmacokinetic profile of voriconazole in patients with COVID-19-associated pulmonary aspergillosis (CAPA) to optimize dosing strategies.... |
PMC7558350 | core_pubmed_pmc | Pharmacokinetics of Shikimic Acid Following Intragastric and Intravenous Administrations in Rats | Pharmacokinetics of Shikimic Acid Following Intragastric and Intravenous Administrations in Rats Abstract Shikimic acid, a critical starting material for the semi-total synthesis of oseltamivir to treat and prevent influenza, exerts many pharmacological effects. However, the optimal bioanalytical method has not been ad... |
PMC5216828 | core_pubmed_pmc | Tumor refractoriness to anti-VEGF therapy | Tumor refractoriness to anti-VEGF therapy Abstract Abstract Vascular endothelial growth factor (VEGF) has been identified as the most potent cytokine involved in tumor angiogenesis and metastasis formation. Clinical results of anti-angiogenic therapies targeting VEGF and its receptors are very modest, resulting in a mo... |
PMC8444299 | core_pubmed_pmc | Prediction Model of Clearance by a Novel Quantitative Structure–Activity Relationship Approach, Combination DeepSnap-Deep Learning and Conventional Machine Learning | Prediction Model of Clearance by a Novel Quantitative Structure–Activity Relationship Approach, Combination DeepSnap-Deep Learning and Conventional Machine Learning Abstract Abstract Some targets predicted by machine learning (ML) in drug discovery remain a challenge because of poor prediction. In this study, a new pre... |
PMC6359657 | core_pubmed_pmc | Effect of Shape on Mesoporous Silica Nanoparticles for Oral Delivery of Indomethacin | Effect of Shape on Mesoporous Silica Nanoparticles for Oral Delivery of Indomethacin Abstract The use of mesoporous silica nanoparticles (MSNs) in the field of oral drug delivery has recently attracted greater attention. However, there is still limited knowledge about how the shape of MSNs affects drug delivery capacit... |
PMC12715525 | core_pubmed_pmc | Nanocarrier-based delivery of siRNA therapeutics in rheumatoid arthritis: immune mechanisms and translational perspectives | Nanocarrier-based delivery of siRNA therapeutics in rheumatoid arthritis: immune mechanisms and translational perspectives Abstract Abstract Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation, pannus formation, and progressive joint destruction. Conventional ther... |
PMC10985144 | core_pubmed_pmc | Design, synthesis, and evaluation of the novel ozagrel–paeonol codrug with antiplatelet aggregation activities as a potent anti-stroke therapeutic agent | Design, synthesis, and evaluation of the novel ozagrel–paeonol codrug with antiplatelet aggregation activities as a potent anti-stroke therapeutic agent Abstract Abstract Introduction: Ischemic stroke is the second most common chronic disease worldwide and is associated with high morbidity and mortality. Thromboembolis... |
PMC10041592 | core_pubmed_pmc | First-in-human clinical trial of the NKT cell-stimulatory glycolipid OCH in multiple sclerosis | First-in-human clinical trial of the NKT cell-stimulatory glycolipid OCH in multiple sclerosis Abstract Background: Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system that causes the damage to the myelin sheath as well as axonal degeneration. Individuals with MS appear to have c... |
PMC11394651 | core_pubmed_pmc | Immune Cell Molecular Pharmacodynamics of Lanreotide in Relation to Treatment Response in Patients with Gastroenteropancreatic Neuroendocrine Tumors | Immune Cell Molecular Pharmacodynamics of Lanreotide in Relation to Treatment Response in Patients with Gastroenteropancreatic Neuroendocrine Tumors Abstract Simple Summary Somatostatin analogs like lanreotide are considered first-line agents for the treatment of gastroenteropancreatic neuroendocrine tumors (NET). Alth... |
PMC3564886 | core_pubmed_pmc | American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates | American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates Abstract Abstract The American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference Short Course “Translational Challenges in Dev... |
PMC9678384 | core_pubmed_pmc | A natural history study to track brain and spinal cord changes in individuals with Friedreich’s ataxia: TRACK-FA study protocol | A natural history study to track brain and spinal cord changes in individuals with Friedreich’s ataxia: TRACK-FA study protocol Abstract Abstract Introduction Drug development for neurodegenerative diseases such as Friedreich’s ataxia (FRDA) is limited by a lack of validated, sensitive biomarkers of pharmacodynamic res... |
PMC3868978 | core_pubmed_pmc | PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST | PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST Abstract A modeling framework relating exposure, biomarkers (vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor (sVEGFR)-2, -3, soluble stem cell factor receptor (sKIT... |
PMC6710871 | core_pubmed_pmc | A rapid and sensitive UPLC-MS/MS method for the determination of flibanserin in rat plasma: application to a pharmacokinetic study | A rapid and sensitive UPLC-MS/MS method for the determination of flibanserin in rat plasma: application to a pharmacokinetic study Abstract Abstract Background In this work, we aim to develop and validate a fast, simple, and sensitive method for the quantitative determination of flibanserin and the exploration of its p... |
PMC10259795 | core_pubmed_pmc | Population pharmacokinetics of benznidazole in neonates, infants and children using a new pediatric formulation | Population pharmacokinetics of benznidazole in neonates, infants and children using a new pediatric formulation Abstract Background There is a major need for information on pharmacokinetics (PK) of benznidazole (BNZ) in children with Chagas disease (CD). We conducted a multicentre population PK, safety and efficacy stu... |
PMC10867129 | core_pubmed_pmc | New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Liver Transplantation: Clinical Perspectives, Toxicity, and PK/PD Properties | New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Liver Transplantation: Clinical Perspectives, Toxicity, and PK/PD Properties Abstract Antimicrobial resistance is a growing global health problem, and it is especially relevant among liver transplant recipients where infections, particularly when cau... |
PMC9031051 | core_pubmed_pmc | Population Pharmacokinetics of Valproic Acid in Pediatric and Adult Caucasian Patients | Population Pharmacokinetics of Valproic Acid in Pediatric and Adult Caucasian Patients Abstract Abstract (1) Background: The aim of this study was to explore the valproic acid (VPA) pharmacokinetic characteristics in a large population of pediatric and adult Caucasian patients and to establish a robust population pharm... |
PMC5423998 | core_pubmed_pmc | Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics | Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics Abstract Purpose The purpose of the study is to evaluate the effect of renal impairment (RI) and end-stage renal disease (ESRD) on the pharmacokinetics (PK) of isavuconazole and the inactive cleavage product, BAL8728. Methods ... |
PMC10005307 | core_pubmed_pmc | Design of Novel Phosphatidylinositol 3-Kinase Inhibitors for Non-Hodgkin’s Lymphoma: Molecular Docking, Molecular Dynamics, and Density Functional Theory Studies on Gold Nanoparticles | Design of Novel Phosphatidylinositol 3-Kinase Inhibitors for Non-Hodgkin’s Lymphoma: Molecular Docking, Molecular Dynamics, and Density Functional Theory Studies on Gold Nanoparticles Abstract Non-Hodgkin’s lymphomas are a diverse collection of lymphoproliferative cancers that are much less predictable than Hodgkin’s l... |
PMC10766027 | core_pubmed_pmc | Time‐dependent clearance can confound exposure–response analysis of therapeutic antibodies: A comprehensive review of the current literature | Time‐dependent clearance can confound exposure–response analysis of therapeutic antibodies: A comprehensive review of the current literature Abstract Abstract Exposure–response (ER) analysis is used to optimize dose and dose regimens during clinical development. Characterization of relationships between drug exposure a... |
PMC6131124 | core_pubmed_pmc | New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment | New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment Abstract Abstract Background The antibacterial agent prulifloxacin, a prodrug of ulifloxacin, is indicated in the treatment of acute lower urinary tract infections, acute... |
PMC5811915 | core_pubmed_pmc | No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers | No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers Abstract Abstract Vorapaxar is a first‐in‐class antagonist of the protease‐activated receptor‐1, the primary thrombin receptor on human platelets, which mediates the downstream effects o... |
PMC10220769 | core_pubmed_pmc | Delivery Systems in Ocular Retinopathies: The Promising Future of Intravitreal Hydrogels as Sustained-Release Scaffolds | Delivery Systems in Ocular Retinopathies: The Promising Future of Intravitreal Hydrogels as Sustained-Release Scaffolds Abstract Slow-release delivery systems are needed to ensure long-term sustained treatments for retinal diseases such as age-related macular degeneration and diabetic retinopathy, which are currently t... |
PMC10801391 | core_pubmed_pmc | Maribavir: Mechanism of action, clinical, and translational science | Maribavir: Mechanism of action, clinical, and translational science Abstract Abstract Maribavir is an oral benzimidazole riboside for treatment of post‐transplant cytomegalovirus (CMV) infection/disease that is refractory to prior antiviral treatment (with or without resistance). Through competitive inhibition of adeno... |
PMC5764295 | core_pubmed_pmc | Evaluation of pharmacokinetic, pharmacodynamic, efficacy, and safety data of low-dose ticagrelor versus standard dose in East Asians: a systematic review | Evaluation of pharmacokinetic, pharmacodynamic, efficacy, and safety data of low-dose ticagrelor versus standard dose in East Asians: a systematic review Abstract Abstract East Asians are prone to higher systemic exposure and increased risk of bleeding compared to other races after administration of antiplatelet agent(... |
PMC5767093 | core_pubmed_pmc | Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis | Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis Abstract Methotrexate (MTX) is one of the mainstays of treatment for several immune-mediated inflammatory joint and skin diseases, especially rheumatoid arthritis (RA) and moderate-to-severe psoriasis. Oral MTX has been used for the treatment ... |
PMC3824340 | core_pubmed_pmc | Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects | Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects Abstract Background and Objectives Dyslipidaemia is a major cardiovascular risk factor associated with type 2 diabetes mellitus. Saroglitazar (ZYH1) is a novel ... |
PMC10185764 | core_pubmed_pmc | Case report: Hepatotoxicity and nephrotoxicity induced by methotrexate in a paediatric patient, what is the role of precision medicine in 2023? | Case report: Hepatotoxicity and nephrotoxicity induced by methotrexate in a paediatric patient, what is the role of precision medicine in 2023? Abstract Methotrexate is an immunosuppressant and chemotherapeutic agent used in the treatment of a range of autoimmune disorders and cancers. Its main serious adverse effects,... |
PMC3756011 | core_pubmed_pmc | Evaluation of Memory Enhancing Clinically Available Standardized Extract of Bacopa monniera on P-Glycoprotein and Cytochrome P450 3A in Sprague-Dawley Rats | Evaluation of Memory Enhancing Clinically Available Standardized Extract of Bacopa monniera on P-Glycoprotein and Cytochrome P450 3A in Sprague-Dawley Rats Abstract Abstract Bacopa monniera is a traditional Ayurvedic herbal medicine used to treat various mental ailments from ancient times. Recently, chemically standard... |
PMC7335847 | core_pubmed_pmc | Design of Phase 3 Studies Evaluating Vixotrigine for Treatment of Trigeminal Neuralgia | Design of Phase 3 Studies Evaluating Vixotrigine for Treatment of Trigeminal Neuralgia Abstract Abstract Purpose Vixotrigine (BIIB074) is a voltage- and use-dependent sodium channel blocker. These studies will evaluate the efficacy and safety of vixotrigine in treating pain experienced by patients with trigeminal neura... |
PMC6415470 | core_pubmed_pmc | Expanding Pharmacist and Student Pharmacist Access to Genetics/Genomics/Pharmacogenomics Competency Education | Expanding Pharmacist and Student Pharmacist Access to Genetics/Genomics/Pharmacogenomics Competency Education Abstract Background: As pharmacogenomics (PGx), a component of genetics/genomics and precision medicine, gains traction in the clinical setting, education of health care providers and health professions student... |
PMC11053983 | core_pubmed_pmc | Beyond One-Size-Fits-All: Tailoring Teicoplanin Regimens for Normal Renal Function Patients Using Population Pharmacokinetics and Monte Carlo Simulation | Beyond One-Size-Fits-All: Tailoring Teicoplanin Regimens for Normal Renal Function Patients Using Population Pharmacokinetics and Monte Carlo Simulation Abstract Abstract In patients with normal renal function, significant teicoplanin dose adjustments are often necessary. This study aimed to develop a population pharma... |
PMC12822763 | core_pubmed_pmc | Degree of Cyclooxygenase-2 Inhibition Modulates Blood Pressure Response | Degree of Cyclooxygenase-2 Inhibition Modulates Blood Pressure Response Abstract Abstract BACKGROUND: Large clinical trials compared distinct nonsteroidal anti-inflammatory drugs in terms of their risk of adverse cardiovascular events. However, whether pharmacologically equipotent doses were used, that is, whether a si... |
PMC12828427 | core_pubmed_pmc | Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis | Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis Abstract Abstract Background and objectives An allometric miltefosine regimen dosed based on fat-free mass (FFM) is effective and safe in treating children with visceral leishmaniasis (VL). However,... |
PMC7876310 | core_pubmed_pmc | Pharmacokinetics and Pharmacodynamics of Immediate- and Modified-Release Mycophenolic Acid Preparations in Healthy Beagle Dogs | Pharmacokinetics and Pharmacodynamics of Immediate- and Modified-Release Mycophenolic Acid Preparations in Healthy Beagle Dogs Abstract Abstract Background: Mycophenolic acid (MPA) is a broad-acting immunomodulating agent that may be therapeutically beneficial for the treatment of immune-mediated diseases in canine pat... |
PMC12930025 | core_pubmed_pmc | Penicillin allergy de‐labelling in the critical care unit: Simulations to design an intravenous drug provocation test that mirrors the plasma profile of an enteral challenge | Penicillin allergy de‐labelling in the critical care unit: Simulations to design an intravenous drug provocation test that mirrors the plasma profile of an enteral challenge Abstract The majority of penicillin allergy labels are incorrect and a label of penicillin allergy is associated with worse outcomes and increased... |
PMC5552262 | core_pubmed_pmc | A systematic review of the pharmacokinetic and pharmacodynamic interactions of herbal medicine with warfarin | A systematic review of the pharmacokinetic and pharmacodynamic interactions of herbal medicine with warfarin Abstract Abstract Objectives The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions betw... |
PMC9843450 | core_pubmed_pmc | Nonclinical pharmacokinetics and biodistribution of VSV-GP using methods to decouple input drug disposition and viral replication | Nonclinical pharmacokinetics and biodistribution of VSV-GP using methods to decouple input drug disposition and viral replication Abstract Abstract Viral replication places oncolytic viruses (OVs) in a unique niche in the field of drug pharmacokinetics (PK) as their self-amplification obscures exposure-response relatio... |
PMC5414484 | core_pubmed_pmc | Levetiracetam Pharmacokinetics in a Patient with Intracranial Hemorrhage Undergoing Continuous Veno-Venous Hemofiltration | Levetiracetam Pharmacokinetics in a Patient with Intracranial Hemorrhage Undergoing Continuous Veno-Venous Hemofiltration Abstract Abstract Patient: Male, 78 Final Diagnosis: Right thalamic intraparenchymal hemorrhage with intraventricular extension Symptoms: Altered mental status • left sided weakness Medication: Leve... |
PMC11021599 | core_pubmed_pmc | Managing venous thrombosis in a pediatric patient with short bowel and congenital nephrotic syndromes: a case report emphasizing rivaroxaban level monitoring | Managing venous thrombosis in a pediatric patient with short bowel and congenital nephrotic syndromes: a case report emphasizing rivaroxaban level monitoring Abstract Direct Oral Anticoagulants (DOACs) typically exhibit a predictable pharmacokinetic and pharmacodynamic response at a fixed dose, not necessitating monito... |
PMC6182763 | core_pubmed_pmc | A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors | A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors Abstract Abstract Purpose Afatinib, an irreversible ErbB family blocker, has demonstrated preclinical antitumor activity with chemotherapy. Methods As part of a phase I trial in ... |
PMC5149471 | core_pubmed_pmc | A Stochastic Model for the Ethanol Pharmacokinetics | A Stochastic Model for the Ethanol Pharmacokinetics Abstract Background: The aim of this study was to propose a new stochastic model to study the time course of ethanol elimination in human bodies. Methods: The times and amount of alcohol ingested are assumed to be random in controllable intervals. Constant elimination... |
PMC12963761 | core_pubmed_pmc | Magnesium sulfate pharmacology for maternal and critical-care indications: mechanisms, pharmacokinetics, and the therapeutic window | Magnesium sulfate pharmacology for maternal and critical-care indications: mechanisms, pharmacokinetics, and the therapeutic window Abstract Abstract Hypertensive disorders of pregnancy and related critical illnesses remain leading global causes of maternal and perinatal morbidity, and magnesium sulfate is now a corner... |
PMC3792104 | core_pubmed_pmc | Applying Linear and Non-Linear Methods for Parallel Prediction of Volume of Distribution and Fraction of Unbound Drug | Applying Linear and Non-Linear Methods for Parallel Prediction of Volume of Distribution and Fraction of Unbound Drug Abstract Abstract Volume of distribution and fraction unbound are two key parameters in pharmacokinetics. The fraction unbound describes the portion of free drug in plasma that may extravasate, while vo... |
PMC12126552 | core_pubmed_pmc | Saliva-based lacosamide monitoring paves the way toward personalized epilepsy pharmacotherapy | Saliva-based lacosamide monitoring paves the way toward personalized epilepsy pharmacotherapy Abstract Saliva, known for better patient compliance and simpler collection, is ideal for monitoring antiseizure medication (ASM) levels. This study aimed to validate saliva for measuring lacosamide, develop a pharmacokinetic ... |
PMC6339973 | core_pubmed_pmc | Anti‐IL‐7 receptor α monoclonal antibody (GSK2618960) in healthy subjects – a randomized, double‐blind, placebo‐controlled study | Anti‐IL‐7 receptor α monoclonal antibody (GSK2618960) in healthy subjects – a randomized, double‐blind, placebo‐controlled study Abstract Abstract Aim Interleukin (IL)‐7 signalling modulates T cell activity and is implicated in numerous autoimmune diseases. The present study investigated the safety, pharmacokinetics, t... |
PMC12657159 | core_pubmed_pmc | A model to simulate human cardio-respiratory responses to ketamine analgesia | A model to simulate human cardio-respiratory responses to ketamine analgesia Abstract Abstract In large-scale combat operations, decision-support systems based on artificial intelligence technology can augment the capability and capacity of medics to care for combat casualties. The development and assessment of such sy... |
PMC6994531 | core_pubmed_pmc | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects Abstract Background and Objective Atacicept is an inhibitor of the B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), and is being studied in relation to im... |
PMC7877833 | core_pubmed_pmc | Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure | Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure Abstract Abstract Heart failure (HF) causes pathological changes in multiple organs, thus affecting the pharmacokinetics (PK) of drugs. The aim of this study was to investigate the PK of candesartan in patients with HF while examining sig... |
PMC10010310 | core_pubmed_pmc | An Informatics Bridge to Improve the Design and Efficiency of Phase I Clinical Trials for Anticancer Drug Combinations | An Informatics Bridge to Improve the Design and Efficiency of Phase I Clinical Trials for Anticancer Drug Combinations Abstract Abstract In this study, we summarized critical databases of drug combination toxicity and pharmacokinetics. We further conducted a feasibility and utility study that demonstrates how different... |
PMC12677336 | core_pubmed_pmc | Pharmacokinetics and Pharmacodynamics of Analgesic and Anesthetic Drugs in Patients During Cardiac Surgery With Cardiopulmonary Bypass: A Narrative Review | Pharmacokinetics and Pharmacodynamics of Analgesic and Anesthetic Drugs in Patients During Cardiac Surgery With Cardiopulmonary Bypass: A Narrative Review Abstract Cardiopulmonary bypass (CPB) impacts pharmacokinetics and -dynamics of drugs used during cardiac surgery. These alterations can lead to changes in drug effi... |
PMC8365968 | core_pubmed_pmc | Determination of myrislignan levels in BALB/c mouse plasma by LC-MS/MS and a comparison of its pharmacokinetics after oral and intraperitoneal administration | Determination of myrislignan levels in BALB/c mouse plasma by LC-MS/MS and a comparison of its pharmacokinetics after oral and intraperitoneal administration Abstract Background Myrislignan is a natural product from Myristica sp. with diverse pharmacological activities. Recently, the anti- Toxoplasma gondii ( T. gondii... |
PMC8698739 | core_pubmed_pmc | MS-222 and Propofol Sedation during and after the Simulated Transport of Nile tilapia ( Oreochromis niloticus ) | MS-222 and Propofol Sedation during and after the Simulated Transport of Nile tilapia ( Oreochromis niloticus ) Abstract Abstract Simple Summary Sedation has been shown to reduce stress and damage during live fish transportation. However, there is a lack of information regarding MS-222 alternatives. The present study a... |
PMC7002806 | core_pubmed_pmc | In-silico activity prediction and docking studies of some 2, 9-disubstituted 8-phenylthio/phenylsulfinyl-9h-purine derivatives as Anti-proliferative agents | In-silico activity prediction and docking studies of some 2, 9-disubstituted 8-phenylthio/phenylsulfinyl-9h-purine derivatives as Anti-proliferative agents Abstract Abstract In-silico activity prediction was performed to predict new inhibitory activities of 2, 9-disubstituted 8-phenylthio/phenylsulfinyl-9h-purine deriv... |
PMC7527669 | core_pubmed_pmc | Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study | Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study Abstract Abstract Objectives The COVID-19 pandemic and the consequent lockdown came as a storm disrupting people’s everyday life. This study aimed at observing whether the COVID-19 related lockdown influenced migraine frequency and ... |
PMC10843602 | core_pubmed_pmc | INJECTABLE LONG-ACTING IVACAFTOR-LOADED POLY (LACTIDE-CO-GLYCOLIDE) MICROPARTICLE FORMULATIONS FOR THE TREATMENT OF CYSTIC FIBROSIS: IN VITRO CHARACTERIZATION AND IN VIVO PHARMACOKINETICS IN MICE | INJECTABLE LONG-ACTING IVACAFTOR-LOADED POLY (LACTIDE-CO-GLYCOLIDE) MICROPARTICLE FORMULATIONS FOR THE TREATMENT OF CYSTIC FIBROSIS: IN VITRO CHARACTERIZATION AND IN VIVO PHARMACOKINETICS IN MICE Abstract Abstract Optimizing a sustained-release drug delivery system for the treatment of cystic fibrosis is crucial for de... |
PMC9513756 | core_pubmed_pmc | Establishing a UHPLC-MS/MS method for evaluation of the influence of stir-frying on the pharmacokinetics of seven compounds in Arctii Fructus | Establishing a UHPLC-MS/MS method for evaluation of the influence of stir-frying on the pharmacokinetics of seven compounds in Arctii Fructus Abstract Abstract At a fundamental level, the broad application of raw and stir-fried Arctii Fructus products as anti-tumor and anti-inflammatory agents is commonly recognized. I... |
PMC3585695 | core_pubmed_pmc | Maximum Tolerated Dose Evaluation of the AMPA Modulator Org 26576 in Healthy Volunteers and Depressed Patients | Maximum Tolerated Dose Evaluation of the AMPA Modulator Org 26576 in Healthy Volunteers and Depressed Patients Abstract Abstract Background A key challenge to dose selection in early central nervous system (CNS) clinical drug development is that patient tolerability profiles often differ from those of healthy volunteer... |
PMC7890388 | core_pubmed_pmc | Prophylactic perioperative cefuroxime levels in plasma and adipose tissue at the time of caesarean section (C-LACE): a protocol for a pilot experimental, prospective study with non-probability sampling to determine interpatient variability | Prophylactic perioperative cefuroxime levels in plasma and adipose tissue at the time of caesarean section (C-LACE): a protocol for a pilot experimental, prospective study with non-probability sampling to determine interpatient variability Abstract Background The aim of the C-LACE study is to measure cefuroxime concent... |
PMC12582597 | core_pubmed_pmc | Epinephrine nasal spray for the treatment of anaphylaxis: perspectives in pediatrics | Epinephrine nasal spray for the treatment of anaphylaxis: perspectives in pediatrics Abstract Abstract Purpose of review Anaphylaxis is a severe allergic reaction characterized by a rapid onset and can be potentially life-threatening. Epinephrine is considered the first-line treatment, and until recently, it was availa... |
PMC12718551 | core_pubmed_pmc | A First‐in‐Human, Single‐ and Multiple‐Dose Study of APG777 , a Half‐Life‐Extended Anti‐ IL ‐13 Monoclonal Antibody, in Healthy Volunteers | A First‐in‐Human, Single‐ and Multiple‐Dose Study of APG777 , a Half‐Life‐Extended Anti‐ IL ‐13 Monoclonal Antibody, in Healthy Volunteers Abstract ABSTRACT Interleukin (IL)‐13 plays a central role in Type 2 inflammation, contributing to the pathogenesis of atopic dermatitis, asthma, and related inflammatory diseases. ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.